Diasorin SpA (CHIX:DIAM) Current Accrued Expense: €0 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:DIAM Diasorin SpA CHIX:DIAM
77 GF Score
Price €66.84
GF Value €88.89
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Diasorin SpA Current Accrued Expense?

Diasorin SpA CHIX:DIAM -4.83% 77 Current Accrued Expense is €0 Mil as of Dec. 2025. GuruFocus rates CHIX:DIAM with a GF Score™ of 77/100 and a GF Value™ of €88.89 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Diasorin SpA's Current Accrued Expense for the quarter that ended in Dec. 2025 was €0 Mil.

Diasorin SpA Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Diasorin SpA's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diasorin SpA Current Accrued Expense Chart

Diasorin SpA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Diasorin SpA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CHIX:DIAM
77GF Score
Diasorin SpA CHIX:DIAM
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diasorin SpA Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of €0 Mil mean?
Diasorin SpA (CHIX:DIAM) has a Current Accrued Expense of €0 Mil as of Dec. 2025. Current Accrued Expense records the total amount of accrued expenses. View historical data on Diasorin SpA and its competitors.
Is Diasorin SpA's Current Accrued Expense too high?
Diasorin SpA's current Current Accrued Expense is €0 Mil. Overall, Diasorin SpA has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diasorin SpA's Current Accrued Expense compare to TMO and DHR?
Diasorin SpA's Current Accrued Expense of €0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Medical Diagnostics & Research company?
A good Current Accrued Expense depends on the Medical Diagnostics & Research industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Diasorin SpA and its competitors. Diasorin SpA's current Current Accrued Expense is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diasorin SpA stock overvalued right now?
Based on GuruFocus' analysis, Diasorin SpA (CHIX:DIAM) is currently considered Modestly Undervalued. The stock's GF Value™ is €88.89, compared to a current price of €66.84 — trading 24.8% below its estimated fair value. The current Current Accrued Expense is €0 Mil. Diasorin SpA's overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Diasorin SpA (CHIX:DIAM), the current Current Accrued Expense is €0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diasorin SpA (CHIX:DIAM) Overvalued in 2026?

Based on GuruFocus' analysis, Diasorin SpA stock appears to be undervalued. The current stock price of €66.84 is trading 24.8% below its estimated GF Value™ of €88.89. GuruFocus considers Diasorin SpA to be Modestly Undervalued.

Key valuation signals for CHIX:DIAM:

  • Current Accrued Expense: €0 Mil
  • GF Value™: €88.89 vs. price of €66.84 (24.8% below fair value)
  • GF Score™: 77/100 with 5 warning signs

No single metric tells the full story. See the CHIX:DIAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Diasorin SpA Business Description

Address Via Crescentino Snc, Saluggia, Vercelli, ITA, 13040
Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment's importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.
77GF Score

Get the complete analysis for CHIX:DIAM

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€66.84
Price
€88.89
GF Value